Key Highlights
• Leadership team in place: Following appointment as Nigel Lange as CEO, key recent hires include a Chief Medical Officer, Head of Medical Affairs, Director of Access Reimbursement, Economics and Assessment and Director of Clinical development
• Finalising data package for HDE submission: Currently finalising an updated dataset which involves a more recent data cut-off point, to support its HDE application to the FDA
• Targeting hospitals in Greater London in the near-term: Pushing forward with launch preparation activities throughout Europe including establishing the Osprey registry
• Additional sales in New Zealand: Following OncoSil’s first ever commercial sale, OncoSil has achieved further sales in New Zealand
• Cash position: Cash balance of $15.3 million as at 31 March 2021
Key Highlights• Leadership team in place: Following appointment...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.1¢ | $65.61K | 5.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 6553895 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1917493 | 5 |
View Market Depth
| Last trade - 15.50pm 16/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |